BackLongview Acquisition II Overview

Longview Acquisition II EBIT

Track Longview Acquisition II's EBIT ($-2.1M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$302.62K
90.52% YoY

As of Sep 30, 2022

Annual EBIT (TTM)

-$2.11M

Trailing 12 months ending Sep 30, 2022

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Longview Acquisition II (LGV) FAQ

Longview Acquisition II (LGV) currently reports a EBIT of $-2.1M as of September 2022. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Longview Acquisition II's EBIT history and peer comparisons.

Longview Acquisition II's EBIT of $-2.1M is lower than the Healthcare sector average of $23B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Longview Acquisition II reported $-2.1M in EBIT as of September 2022. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-2.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Longview Acquisition II, and consider following LGV for alerts when major investors trade the stock.

Longview Acquisition II is classified in the Healthcare sector. On EBIT, it currently shows $-2.1M versus a sector average near $23B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LGV with unrelated industries.